<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03115827</url>
  </required_header>
  <id_info>
    <org_study_id>VUMC54580</org_study_id>
    <nct_id>NCT03115827</nct_id>
  </id_info>
  <brief_title>Norepinephrine-targeted Therapy for Action Control in Parkinson Disease</brief_title>
  <official_title>Norepinephrine-targeted Therapy for Action Control in Parkinson Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Academy of Neurology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether droxidopa, a medication that increases
      norepinephrine levels, may be effective in improving some aspects of cognition and movement
      in Parkinson's disease (PD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects 1 million
      people in the United States. PD causes a variety of disabling symptoms, which impact movement
      as well as cognition. Historically, we have relied on medications that increase dopamine
      levels to treat PD, although we are recognizing more and more that other chemicals in the
      brain are involved in PD as well.

      Droxidopa (Northera) is an approved drug for the treatment of low blood pressure in PD. It is
      a norepinephrine precursor, which is converted in the body to the neurotransmitter
      norepinephrine. This is a chemical that the body normally makes that has a variety of
      important activities in the brain and peripheral nervous system. In PD, the cells that make
      norepinephrine die off as part of the disease process. Therefore, people with PD often have
      low levels of norepinephrine in their blood and in their spinal fluid. Norepinephrine is
      important for maintaining blood pressure, which may be one reason that some people with PD
      have problems with their blood pressure falling too low when they stand up. This can lead to
      symptoms such as dizziness, lightheadedness, feeling faint, or sometimes passing out.

      Droxidopa has been approved by the FDA for the treatment of low blood pressure in Parkinson's
      disease. However, as norepinephrine is also important for a lot of processes that happen in
      the brain as well, we believe that this medication may be also helpful for some of the other
      symptoms of PD. In particular, norepinephrine plays a key role in brain networks that are
      important for attention, decision making, and controlling movements and actions. In order for
      norepinephrine to reach the brain, it must cross the blood-brain barrier. Therefore, in this
      study we will be giving droxidopa along with carbidopa, which stops your body from breaking
      down norepinephrine in the blood stream and allows it to get into the brain. This is a
      medication that is often given in Parkinson's disease along with levodopa in the form of
      carbidopa-levodopa, or Sinemet. This medication works the same way with levodopa in helping
      it get into the brain and improve the symptoms of PD. The only difference is that levodopa
      works like the chemical dopamine, whereas droxidopa works like norepinephrine. Up to this
      point, we have not had a way to correct the low norepinephrine levels in Parkinson's disease.
      Therefore, this study gives us the chance to investigate the effectiveness of a potential new
      treatment for PD patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 18, 2017</start_date>
  <completion_date type="Actual">December 21, 2018</completion_date>
  <primary_completion_date type="Actual">December 21, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a single-arm study enrolling 15 patients that will all receive the experimental treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>All patients will receive the same treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Who Develop an Adverse Event During the 7-week Treatment Period That is Determined to be Likely Related to the Study Medications.</measure>
    <time_frame>7 weeks</time_frame>
    <description>Safety will be defined by the percent of subjects who develop an adverse event during the 7-week treatment period that is determined to be likely related to the study medications.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinue the Study Drug Due to Adverse Effects During the 7-week Treatment Period.</measure>
    <time_frame>7 weeks</time_frame>
    <description>Tolerability will be defined by the number of patients who discontinue the study drug due to adverse effects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>Week 4 to Week 7</time_frame>
    <description>The mean maximum tolerated dose of droxidopa reached by the study participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Compliance</measure>
    <time_frame>7 weeks</time_frame>
    <description>Percent compliance is defined as the percent of study participants who take greater than or equal to 70% of the assigned dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Stop-Signal Reaction Time From Baseline to Week 7</measure>
    <time_frame>baseline and week 7</time_frame>
    <description>The Stop-Signal reaction time is a computerized test that assesses reaction time and response inhibition</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Droxidopa 600mg by mouth twice a day and carbidopa 200mg by mouth twice a day for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Droxidopa</intervention_name>
    <description>Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbidopa</intervention_name>
    <description>Carbidopa 200mg twice a day</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Nondemented man or woman 18 years of age or older with idiopathic PD based on the UK
             Parkinson Disease Society Brain Bank Clinical Diagnostic Criteria (refer to Appendix C
             for the criteria)

          2. Unified Parkinson Disease Rating Scale (UPDRS) motor scores OFF medication consistent
             with postural instability gait difficulty (PIGD) subtype

          3. Symptoms of freezing or falls

          4. Able to walk at least 10 meters

          5. Medically stable outpatient, based on the investigator's judgment

          6. The patient must be willing and able to give written informed consent prior to
             performing any study procedures.

        Exclusion Criteria:

          1. Score of 21 or lower on Montreal Cognitive Assessment

          2. Sustained supine hypertension greater than or equal to 180 mmHg systolic or 110 mmHg
             diastolic, or have these measurements at their Baseline Visit (Visit 2). Sustained is
             defined as measurements persistently greater at 2 separate measurements at least 10
             minutes apart with the subject supine and at rest for at least 5 minutes.

          3. Concomitant use of vasoconstricting agents such as ephedrine, dihydroergotamine, or
             midodrine. Concomitant use of other noradrenergic medications, such as
             serotonin-norepinephrine reuptake inhibitors (SNRI's) is also contraindicated.
             Patients must stop taking these drugs at least 2 days or 5 half-lives (whichever is
             longer) prior to their baseline visit and throughout the duration of the study.

          4. Diagnosis of hypertension that requires treatment with antihypertensive medications
             (short-acting antihypertensives to treat nocturnal supine hypertension are allowed in
             this study)

          5. Women of childbearing potential

          6. Any significant uncontrolled cardiac arrhythmia

          7. History of myocardial infarction, within the past 2 years

          8. Current unstable angina

          9. Congestive heart failure (NYHA Class 3 or 4)

         10. History of cancer within the past 2 years other than a successfully treated,
             non-metastatic cutaneous squamous cell or basal cell carcinoma or cervical cancer in
             situ

         11. History of stroke

         12. Gastrointestinal condition that may affect the absorption of study drug (e.g.,
             ulcerative colitis, gastric bypass)

         13. Musculoskeletal disorders such as severe arthritis, post knee surgery, hip surgery, or
             any other condition that the investigators determine may impair assessment of gait

         14. History of myocardial infarction, uncontrolled cardiac arrhythmia, unstable angina,
             congestive heart failure, or stroke

         15. Untreated closed angle glaucoma

         16. Musculoskeletal or other disorders that may impair assessment of gait

         17. Any major surgical procedure within 30 days prior to the Baseline visit

         18. Previously treated with droxidopa within 30 days prior to the Baseline visit

         19. Currently receiving any other investigational drug or have received an investigational
             drug within 60 days prior to the Baseline visit

         20. Known or suspected alcohol or substance abuse within the past 12 months (DSM-IV
             definition of alcohol or substance abuse)

         21. Any condition or laboratory test result, which in the Investigator's judgment, might
             result in an increased risk to the patient, or would affect their participation in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine McDonell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 9, 2017</study_first_submitted>
  <study_first_submitted_qc>April 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <results_first_submitted>December 20, 2019</results_first_submitted>
  <results_first_submitted_qc>January 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2020</results_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Katherine Eder McDonell</investigator_full_name>
    <investigator_title>Assistant Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Droxidopa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 31, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT03115827/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1</title>
          <description>Droxidopa 600mg by mouth twice a day and carbidopa 200mg by mouth twice a day for 4 weeks
Droxidopa: Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day
Carbidopa: Carbidopa 200mg twice a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>Droxidopa 600mg by mouth twice a day and carbidopa 200mg by mouth twice a day for 4 weeks
Droxidopa: Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day
Carbidopa: Carbidopa 200mg twice a day</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.6" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Develop an Adverse Event During the 7-week Treatment Period That is Determined to be Likely Related to the Study Medications.</title>
        <description>Safety will be defined by the percent of subjects who develop an adverse event during the 7-week treatment period that is determined to be likely related to the study medications.</description>
        <time_frame>7 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Droxidopa 600mg by mouth twice a day and carbidopa 200mg by mouth twice a day for 4 weeks
Droxidopa: Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day
Carbidopa: Carbidopa 200mg twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Develop an Adverse Event During the 7-week Treatment Period That is Determined to be Likely Related to the Study Medications.</title>
          <description>Safety will be defined by the percent of subjects who develop an adverse event during the 7-week treatment period that is determined to be likely related to the study medications.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinue the Study Drug Due to Adverse Effects During the 7-week Treatment Period.</title>
        <description>Tolerability will be defined by the number of patients who discontinue the study drug due to adverse effects.</description>
        <time_frame>7 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Droxidopa 600mg by mouth twice a day and carbidopa 200mg by mouth twice a day for 4 weeks
Droxidopa: Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day
Carbidopa: Carbidopa 200mg twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinue the Study Drug Due to Adverse Effects During the 7-week Treatment Period.</title>
          <description>Tolerability will be defined by the number of patients who discontinue the study drug due to adverse effects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Participants that discontinued due to SAEs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Participants that discontinued due to mild AEs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Participants that did not discontinue</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Tolerated Dose</title>
        <description>The mean maximum tolerated dose of droxidopa reached by the study participants</description>
        <time_frame>Week 4 to Week 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Droxidopa 600mg by mouth twice a day and carbidopa 200mg by mouth twice a day for 4 weeks
Droxidopa: Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day
Carbidopa: Carbidopa 200mg twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose</title>
          <description>The mean maximum tolerated dose of droxidopa reached by the study participants</description>
          <units>mg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1053" spread="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Compliance</title>
        <description>Percent compliance is defined as the percent of study participants who take greater than or equal to 70% of the assigned dosage</description>
        <time_frame>7 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Droxidopa 600mg by mouth twice a day and carbidopa 200mg by mouth twice a day for 4 weeks
Droxidopa: Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day
Carbidopa: Carbidopa 200mg twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Compliance</title>
          <description>Percent compliance is defined as the percent of study participants who take greater than or equal to 70% of the assigned dosage</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Stop-Signal Reaction Time From Baseline to Week 7</title>
        <description>The Stop-Signal reaction time is a computerized test that assesses reaction time and response inhibition</description>
        <time_frame>baseline and week 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Droxidopa 600mg by mouth twice a day and carbidopa 200mg by mouth twice a day for 4 weeks
Droxidopa: Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day
Carbidopa: Carbidopa 200mg twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Stop-Signal Reaction Time From Baseline to Week 7</title>
          <description>The Stop-Signal reaction time is a computerized test that assesses reaction time and response inhibition</description>
          <units>change in SSRT in seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.38" spread="40.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>11 weeks</time_frame>
      <desc>The definitions used to collect the adverse event information does not differ from the clinicaltrials.gov definitions. Serious adverse event information was collected over the phone at the time of onset. Adverse Event information was collected at each study visit including baseline, visit 1, visit 2, visit 3, and the follow-up visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>Droxidopa 600mg by mouth twice a day and carbidopa 200mg by mouth twice a day for 4 weeks
Droxidopa: Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day
Carbidopa: Carbidopa 200mg twice a day</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>transient cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>ventral hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival Hemhorrage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Influenza-like symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Freezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Increased Uncoordinated Movements</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Increased Foot Dystonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Brief Confusional Episode</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was an open-label, dose-titration, safety and tolerability pilot study with a small sample size (n=15). Additionally, there was no placebo arm or comparison group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Katherine McDonell</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>615-875-7987</phone>
      <email>katherine.mcdonell@vumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

